Presenting Author: Meghan C. Towne, MS, CGC
Take home points:
- The Patient for Life Program demonstrated a 19% relative increase in diagnostic yield, primarily driven by proactive, lab-initiated reanalysis based on emerging gene-disease relationship evidence.
- New gene-disease relationships were the most significant factor in reclassifications, accounting for 64% of upgrades.
- Nearly ½ (45%) of upgrades were clinically significant upgrades, moving from uncertain or negative to positive.